The Society of Gynecologic Oncology (SGO) and the Association of Community Cancer Centers (ACCC) have been awarded a joint independent medical education grant from AstraZeneca and Merck. Together, SGO and ACCC will offer four accredited webinars (live and enduring) and up to six additional non-accredited media presentations on the topic of delivering personalized medicine in a community setting.
Conversations in the Clinic: Patient Perspectives on Genetic Testing
Listeners will learn about the importance of genetic testing for ovarian cancer from a genetic counselor and a physician, and most importantly, from a patient.
Moderator: Ashley Stuckey, MD
Speakers: Todd Tillmanns, MD, FACOG, West Cancer Center, and Leigha Senter-Jamieson, MS, CGC, The Ohio State University Wexner Medical Center.
William Burke, MD, Stony Brook University Cancer Center
Melissa Hardesty, MD, MPH, Alaska Women’s Cancer Care
Premal Thaker, MD, MS, Washington University in St. Louis, Siteman Cancer Center
Ashley Stuckey, MD, Brown University, Women and Infants Hospital
Todd Tillmanns, MD, FACOG, West Cancer Center
Jeff Lin, MD, City of Hope Medical Group
Roisin O’Cearbhaill, MD, Memorial Sloan Kettering Cancer Center
Charles Drescher, MD, Swedish Cancer Institute
John Farley, MD, COL, FACOG, FACS, Dignity Health Cancer Institute, St. Joseph’s Hospital and Medical Center
Leigha Senter-Jamieson, MS, CGC, The Ohio State University Wexner Medical Center
Medical oncologists, gynecologic oncologists, obstetrician-gynecologists, primary care physicians, advanced practice providers (nurse practitioners, physician assistants, oncology pharmacists), oncology nurses, pathologists, and other healthcare professionals (HCPs) involved in treating patients with ovarian cancer.
At the end of this educational initiative, participants should be able to:
The live/online webinars will each offer the following credits:
Non-accredited educational materials: podcasts, case reviews, and other educational resources/tools.
The impact of participating in this initiative on clinical performance related to the optimal management of ovarian cancer will be assessed by comparing the response for pre-activity and post-activity tests (also designed by the Steering Committee). The outcomes analysis will assess the effectiveness of the programs in changing knowledge and competence, and intent to change behavior among learners in the following areas:
If you have any questions or feedback about this project, please contact Sandra Megally, Senior Program Manager.
This activity is supported by independent medical education grants from AstraZeneca and Merck.